Welcome to our dedicated page for ReShape Lifesciences SEC filings (Ticker: RSLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
RSLS-associated SEC filings document the public-company record that includes filings by Vyome Holdings, Inc., including governance votes, capital-structure proposals, and material-event reports. Definitive proxy statements cover director elections, authorized-share amendments, auditor ratification, and executive-compensation advisory votes.
Recent 8-K and 8-K/A filings disclose Regulation FD investor-presentation materials, material definitive agreements involving subsidiaries and convertible-note assets, registered security information, and corrected unaudited pro forma condensed combined financial statements. The record also includes formal amendments to previously filed event reports.
On August 7, 2025 ReShape Lifesciences reconvened a special meeting that had been partially adjourned on July 24, 2025 to complete voting on two proposals tied to a strategic transaction. Stockholders approved the sale of substantially all of the Company’s assets to Ninjour Health International Limited, an affiliate of Biorad Medisys, Pvt. Ltd., with 1,273,715 votes for, 26,206 against and 2,305 abstentions. Shareholders also approved amendments to Article VI of the Company’s Restated Certificate of Incorporation related to the proposed merger with Vyome Therapeutics, Inc., with 1,240,191 votes for, 58,555 against and 3,480 abstentions. The approved amendments are set to take effect substantially concurrently with the Merger’s effective time.
ReShape Lifesciences (RSLS) is asking its shareholders to approve two transformative transactions: (i) a reverse-merger with privately held Vyome Therapeutics and (ii) the sale of substantially all ReShape operating assets to U.K.-based Biorad for $2.25 million cash plus working-capital adjustments. At closing, Merger Sub will combine with Vyome, Vyome will survive as a wholly-owned subsidiary, and the parent will be renamed Vyome Holdings, Inc. The exchange ratio will be set 10 days before the special meeting so that Vyome security-holders own 88.9-92.31% of the fully-diluted shares, leaving current ReShape holders with 7.69-11.1%, subject to a net-cash true-up against a $5 million target.
ReShape’s balance-sheet assets (other than cash) and virtually all liabilities will transfer to Biorad, simplifying the combined company’s capital structure and sharpening its focus on Vyome’s immuno-inflammatory pipeline. ReShape has already loaned Vyome $400,000 at 8% interest to cover merger expenses; the note will be forgiven at closing but becomes senior secured if the deal fails due to financing issues. To retain a Nasdaq listing, the combined company must satisfy initial listing standards, including a $4.00 minimum share price; if approved, the ticker is expected to change to “HIND.”
ReShape will hold a virtual special meeting where shareholders will vote on (1) issuing new shares for the merger and (2) approving the asset sale. Vyome has already secured written consent from >50% of its voting shares, so no Vyome meeting is required. The boards of both companies unanimously recommend voting “FOR” all proposals, but completion remains contingent on shareholder approval and Nasdaq acceptance.
ReShape Lifesciences (Nasdaq: RSLS) filed an 8-K (Item 8.01 – Other Events) disclosing its current status with Nasdaq listing requirements. On May 28 2025 the company received a delisting notice for failing to meet the Nasdaq Capital Market’s minimum $2.5 million stockholders’ equity requirement; equity stood at only $1.2 million as of March 31 2025.
Since the notice, ReShape raised additional capital in two transactions: (1) 593,000 common shares sold between June 3–6 2025 via its at-the-market program for $3.64 million gross proceeds, and (2) an offering completed June 9 2025 of 1,054,604 shares for $2.64 million gross proceeds. Pro forma for these raises, management states that stockholders’ equity now exceeds $2.5 million.
The company has requested a hearing before a Nasdaq Hearings Panel, which automatically stays any suspension or delisting action until the Panel issues a decision and any permitted extension period expires. Management cautions that merely surpassing the equity threshold does not guarantee continued listing; the final outcome depends on the Panel’s review.
Investors should monitor the Panel’s ruling and ReShape’s ability to sustain equity levels, as delisting would shift trading to an over-the-counter venue and could impact liquidity and valuation.